EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus

Hongtao Yu iD, Victoria Parker, Viknesh Selvarajah, Lars Hansen, Darren Robertson, Bengt Hamrén, Anis Khan iD, Joanna Parkinson iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70093 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Hongtao Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Models, Biological, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cotadutide is a dual glucagon‐like peptide‐1/glucagon receptor agonist. The objective of the analysis was to develop a pharmacokinetic‐pharmacodynamic (PK/PD) model to describe the relationship between cotadutide exposure and response on urine albumin‐to‐creatinine ratio (UACR), urinary albumin (UALB), and body weight in participants with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) using data from a Phase2b study (NCT04515849).

Methods

A total of 247 participants with CKD and T2DM were randomized and titrated to either 100, 300 or 600 μg cotadutide, 1 mg semaglutide or placebo. UACR was measured biweekly from either morning void (Weeks 14 and 26) or spot urine (other visits). The analysis was implemented using a longitudinal non‐linear mixed‐effect model. The potential impact of covariates on efficacy in participants was quantified.

Results

PK/PD models were developed, and a significant relationship was identified between cotadutide exposure and PD biomarkers of UACR, UALB and body weight. The models described the data adequately; greater changes in PD responses were observed with higher cotadutide doses. Baseline mean blood pressure and baseline UALB were found to affect the reductions in UACR and UALB, respectively. Model‐predicted relative change from placebo in UACR, UALB and body weight after 26 weeks of 600 μg cotadutide treatment were −45.6% (−52.4%, −38.7%), −47.2% (−56.0%, −39.9%) and −5.3% (−7.6%, −4.1%), respectively.

Conclusions

This modelling assessment was successfully applied for cotadutide to understand the relationship between cotadutide dosing regimen and the response in UACR, UALB and body weight. These models have general application in analysing and interpreting data from CKD/diabetic kidney disease (DKD) studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicModels, BiologicalHypoglycemic AgentsGlucagon-Like PeptidesHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodDose-Response Relationship, DrugAlbuminuriaAdultBody WeightCreatinineGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Stichwörter der Autor:innen

chronic kidney diseasemodelling and simulationpharmacokinetic‐pharmacodynamic

Substanzen

Hypoglycemic AgentsGlucagon-Like PeptidesCreatinineGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Early Clinical Development, R&D, AstraZeneca, Cambridge, UK.
  • Early Clinical Development, R&D, AstraZeneca, Gaithersburg, UK.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Hongtao Yu, Anis Khan, Joanna Parkinson

Förderung

  • AstraZeneca

Zitieren

APA

Yu, H., Parker, V., Selvarajah, V., Hansen, L., Robertson, D., Hamrén, B., Khan, A., & Parkinson, J. (2025). Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70093

Vancouver

Yu H, Parker V, Selvarajah V, Hansen L, Robertson D, Hamrén B, et al. Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70093

BibTeX
@article{Yu2025,
  author = {Yu, Hongtao and Parker, Victoria and Selvarajah, Viknesh and Hansen, Lars and Robertson, Darren and Hamrén, Bengt and Khan, Anis and Parkinson, Joanna},
  title = {Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70093}
}
Kostenlos starten →